Mrak M; Pavšič N; Žižek D; Ležaić L; Bunc M;

Journal of cardiovascular development and disease [J Cardiovasc Dev Dis] 2023 May 26; Vol. 10 (6).
Date of Electronic Publication: 2023 May 26.

Coronary sinus reducer (CSR) implantation is a new treatment option for patients with refractory angina pectoris. However, there is no evidence from a randomized trial that would show an improvement in exercise capacity after this treatment.
The aim of this study was to evaluate the influence of CSR treatment on maximal oxygen consumption and compare it to a sham procedure.
Twenty-five patients with refractory angina pectoris (Canadian Cardiovascular Society (CCS) class II-IV) were randomized to a CSR implantation ( n = 13) or a sham procedure ( n = 12). At baseline and after 6 months of follow-up, the patients underwent symptom-limited cardiopulmonary exercise testing with an adjusted ramp protocol and assessment of angina pectoris using the CCS scale and Seattle angina pectoris questionnaire (SAQ). In the CSR group, maximal oxygen consumption increased from 15.56 ± 4.05 to 18.4 ± 5.2 mL/kg/min ( p = 0.03) but did not change in the sham group ( p = 0.53); p for intergroup comparison was 0.03. In contrast, there was no difference in the improvement of the CCS class or SAQ domains.
To conclude, in patients with refractory angina and optimized medical therapy, CSR implantation may improve oxygen consumption beyond that of optimal medical therapy.